beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities

Authors: van Kuilenburg, André B.P.1; Meinsma, Rutger1; Beke, Eva1; Assmann, Birgit2; Ribes, Antonia3; Lorente, Isabel4; Busch, Rebekka5; Mayatepek, Ertan2; Abeling, Nico G.G.M.1; van Cruchten, Arno1; Stroomer, Alida E.M.1; van Lenthe, Henk1; Zoetekouw, Lida1; Kulik, Willem1; Hoffmann, Georg F.6; Voit, Thomas7; Wevers, Ron A.8; Rutsch, Frank5; van Gennip, Albert H.9

Source: Human Molecular Genetics, Volume 13, Number 22, 15 November 2004 , pp. 2793-2801(9)

Publisher: Oxford University Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

beta-Ureidopropionase deficiency is an inborn error of the pyrimidine degradation pathway, affecting the cleavage of N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid. In this study, we report the elucidation of the genetic basis underlying a beta-ureidopropionase deficiency in four patients presenting with neurological abnormalities and strongly elevated levels of N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid in plasma, cerebrospinal fluid and urine. No beta-ureidopropionase activity could be detected in a liver biopsy obtained from one of the patients, which reflected the complete absence of the beta-ureidopropionase protein. Analysis of the beta-ureidopropionase gene (UPB1) of these patients revealed the presence of two splice-site mutations (IVS1-2A>G and IVS8-1G>A) and one missense mutation (A85E). Heterologous expression of the mutant enzyme in Escherichia coli showed that the A85E mutation resulted in a mutant beta-ureidopropionase enzyme without residual activity. Our results demonstrate that the N-carbamyl-beta-amino aciduria in these patients is due to a deficiency of beta-ureidopropionase, which is caused by mutations in the UPB1 gene. Furthermore, an altered homeostasis of beta-aminoisobutyric acid and/or increased oxidative stress might contribute to some of the clinical abnormalities encountered in patients with a beta-ureidopropionase deficiency. An analysis of the presence of the two splice site mutations and the missense mutation in 95 controls identified one individual who proved to be heterozygous for the IVS8-1G>A mutation. Thus, a beta-ureidopropionase deficiency might not be as rare as is generally considered.

Keywords: Apoptosis; Bcl-2; chloroplast; herbicide

Document Type: Research article

DOI: 10.1093/hmg/ddh303

Affiliations: 1: Department of Clinical Chemistry, Academic Medical Center, Emma Children's Hospital, The Netherlands, 2: Department of General Pediatrics, University Children's Hospital, Düsseldorf, Germany, 3: Institut de Bioquímica Clínica, CDB, Hospital Clínic, Barcelona, Spain, 4: Hospital Parc Taulí, Sabadell, Barcelona, Spain, 5: Klinik für Kinder- und Jugendmedizin, Klinikum Dortmund gGmbH, Dortmund, Germany, 6: Department of Pediatrics, University Hospital Heidelberg, Heidelberg, Germany, 7: Department of Pediatrics, University Hospital Essen, Essen, Germany, 8: Institute of Neurology, University Medical Center Nijmegen, Nijmegen, The Netherlands and 9: Departments of Clinical Genetics and Clinical Chemistry, Academic Hospital Maastricht, Maastricht, The Netherlands

We were unable to expand this article. Please try again later. If the problem continues, please contact help@ingentaconnect.com.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$48.47 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A